These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Acoramidis in Transthyretin Amyloid Cardiomyopathy. Reply. Gillmore JD; Lystig T; Fox JC N Engl J Med; 2024 Apr; 390(14):1346-1347. PubMed ID: 38598813 [No Abstract] [Full Text] [Related]
5. Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". Kazi DS; Bellows BK; Spertus JA; Baron SJ; Shen C; Cohen DJ; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ Circulation; 2020 Oct; 142(15):e212-e213. PubMed ID: 33044859 [No Abstract] [Full Text] [Related]
6. Patisiran in Patients with Transthyretin Cardiac Amyloidosis. Martínez-Sellés M N Engl J Med; 2024 Jan; 390(3):286. PubMed ID: 38231632 [No Abstract] [Full Text] [Related]
9. Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous. Bezerra F; Simões CJV; Beirão JM; Saraiva MJ; Brito RMM; Almeida MR Amyloid; 2019; 26(sup1):73-74. PubMed ID: 31343304 [No Abstract] [Full Text] [Related]
10. Amyloidotic breast nodule in hereditary transthyretin amyloidosis (hATTR): a case report. Cisneros-Barroso E; Losada-López I; González-Moreno J; Buades J; Ferrer-Nadal A; Ripoll-Vera T; Usón M; Figuerola A; Montalà JC; Descals C; Salva-Ramonell F; Torres-Rovira J; Gene-Heym A; Fernández-Burgos I; Soler T Amyloid; 2019; 26(sup1):59-60. PubMed ID: 31343326 [No Abstract] [Full Text] [Related]
11. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report. Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280 [No Abstract] [Full Text] [Related]
12. Electrochemical skin conductance in hereditary amyloidosis related to transthyretin V30M - a promising tool to assess treatment efficacy? Castro J; Costa J; de Castro I; Conceição I Amyloid; 2018 Dec; 25(4):267-268. PubMed ID: 30773060 [No Abstract] [Full Text] [Related]
13. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule. Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370 [No Abstract] [Full Text] [Related]
14. Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS. Simões CJV; Almeida ZL; Cardoso AL; Bezerra F; Almeida MR; Beirão J; Pinho E Melo TMVD; Saraiva MJ; Brito RMM Amyloid; 2019; 26(sup1):77-78. PubMed ID: 31343302 [No Abstract] [Full Text] [Related]